［1］Torre LA，Bray F，Sieqel RL，et al.Global cancer statistics，2012［J］.CA Cancer J Clin，2015，65(2)：87-108.
［2］Rak J，Yu JL，Luyendyk J，et al.Oncogenes，trousseau syndrome，and cancer-related change in the coagulome of mice and humans［J］.Cancer Res，2006，66(22)：10643-10646.
［3］Korte W.Cancer and thrombosis：an increasingly important association［J］.Support Care Cancer，2008，16（3）：223-228.
［4］Khosa F，Otero HJ，Prevedello LM，et al.Imaging presentation of venous thrombosis in patients with cancer［J］.AJR Am J Roentgenol，2010，194(4)：1099-1108.
［5］Tas F，Kilic L，Bilgin E，et al.Clinical and prognostic significance of coagulation assays in advanced epithelial ovarian cancer［J］.Int J Gynecol Cancer，2013，23（2）：276-281.
［6］Dammacco F，Vacca A，Procaccio P，et al.Cancer-related coagulopathy (Trousseau's syndrome)：review of the literature and experience of a single center of internal medicine［J］.Clin Exp Med，2013，13（2）：85-97.
［7］Carrier M，Le Gal G，Wells PS，et al.Systematic review：The Trousseau syndrome revisited：should we screen extensively for cancer in patients with venous thromboembolism［J］?Ann Int Med，2008，149(5)：323-333.
［8］Lyman GH，Khorana AA，Falanga A，et al.American Society of Clinical Oncology Guideline：recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer［J］.J Clin Oncol，2007，25（34）：5490-5505.
［9］Lee YG，Lee E，Lee KW，et al.Cisplatin-based chemotherapy is a strong risk factor for thromboembolic events in small-cell lung cancer［J］.Cancer Res Treat，2015，10：4143-4148.
［10］Zhao M，Li H，Li L，et al.Effects of a gemcitabine plus platinum regimen combined with a dendritic cell-cytokine induced killer immunotherapy on recurrence and survival rate of non-small cell lung cancer patients［J］.Exp Ther Med，2014，7：1403-1407.
［11］Shi SB，Ma TH，Li CH，et al.Effect of maintenance therapy with dendritic cells：cytokine-induced killer cells in patients with advanced non-small cell lung cancer［J］.Tumori，2012，98（3）：314-319.
［12］Qi YC，Wang DZ，Yang Bo，et al.Preparation and bio-activive assay of CD3AK cell from umbilical blood［J］.Cancer Res Prev Treat，2004，31（7）：381-384.［祁岩超，王得周，杨波，等.脐血CD3AK细胞的制备、生物活性测定及临床应用初探［J］.肿瘤防治研究，2004，31（7）：381-384.］
［13］Bergman PJ.Cancer immunotherapy［J］.Top Companion Anim Med，2009，24（3）：130-136.
［14］Mao DK，Qin HF，Yu AP.et al.Dyamic changes and clinical significance of coagulation，fibrinolytic function and platelet parameter before and after chemotherapy in lung cancer patients［J］.Military Med Sci，2012，36（2）：141-146.［毛德奎，秦海峰，于爱萍，等.肺癌患者化疗前后凝血、纤溶功能与血小板参数的变化及其临床意义［J］.军事医学，2012，36（2）：141-146.］
［15］Dimosthenis A，Georgia P，George P，et al.Predictive value of D-dimer plasma levels in response and progressive disease in patients with lung cancer［J］.Lung Cancer，2006，53：205-210.
［16］Wang RB，Hao YS，Qi BJ，et al.Changes of D-dimer after DC-CIK immunotherapy in-advanced colorectal cancer［J］.Chin J Lab Diag，2014，18（2）：247-250.［王睿斌，郝筱诗，齐保军，等.晚期结直肠癌患者DC-CIK免疫干预前后D-二聚体改变的临床研究［J］.中国实验诊断学，2014，18（2）：247-250.］
［17］Khorana AA，Francis CW，Culakova E，et al.Frequency，risk factors，and trends for venous thromboembolism among hospitalized cancer patients［J］.Cancer，2007，110（10）：2339-2346.